CA 19-9

Jump to: navigation, search

WikiDoc Resources for CA 19-9

Articles

Most recent articles on CA 19-9

Most cited articles on CA 19-9

Review articles on CA 19-9

Articles on CA 19-9 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CA 19-9

Images of CA 19-9

Photos of CA 19-9

Podcasts & MP3s on CA 19-9

Videos on CA 19-9

Evidence Based Medicine

Cochrane Collaboration on CA 19-9

Bandolier on CA 19-9

TRIP on CA 19-9

Clinical Trials

Ongoing Trials on CA 19-9 at Clinical Trials.gov

Trial results on CA 19-9

Clinical Trials on CA 19-9 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CA 19-9

NICE Guidance on CA 19-9

NHS PRODIGY Guidance

FDA on CA 19-9

CDC on CA 19-9

Books

Books on CA 19-9

News

CA 19-9 in the news

Be alerted to news on CA 19-9

News trends on CA 19-9

Commentary

Blogs on CA 19-9

Definitions

Definitions of CA 19-9

Patient Resources / Community

Patient resources on CA 19-9

Discussion groups on CA 19-9

Patient Handouts on CA 19-9

Directions to Hospitals Treating CA 19-9

Risk calculators and risk factors for CA 19-9

Healthcare Provider Resources

Symptoms of CA 19-9

Causes & Risk Factors for CA 19-9

Diagnostic studies for CA 19-9

Treatment of CA 19-9

Continuing Medical Education (CME)

CME Programs on CA 19-9

International

CA 19-9 en Espanol

CA 19-9 en Francais

Business

CA 19-9 in the Marketplace

Patents on CA 19-9

Experimental / Informatics

List of terms related to CA 19-9

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

CA19-9 (carbohydrate antigen 19-9 or sialylated Lewis (a) antigen) is a blood test from the tumor marker category. While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring.[1] Other causes for elevated CA19-9 levels include Mirizzi's syndrome and other hepatobiliary diseases.[2] In patients that have the Lewis antigen blood type, CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9.

References

  1. Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006). "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J. Clin. Oncol. 24 (33): 5313–27. PMID 17060676. 
  2. Robertson A, Davidson B (2007). "Mirizzi syndrome complicating an anomalous biliary tract: a novel cause of a hugely elevated CA19-9". European journal of gastroenterology & hepatology. 19 (2): 167–9. PMID 17273004. 


de:CA 19-9 hr:Karbohidratni antigen 19-9



Linked-in.jpg